Anti-CD20/MS4A1 antibody

Anti-CD20/MS4A1 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit monoclonal to CD20/MS4A1

FCM

Human CD20 / MS4A1

AA960661 antibody; B1 antibody; Bp35 antibody; Cd20 antibody; CD20 antibody; CVID5 antibody; Ms4a2 antibody; S7 antibody; LEU-16 antibody; Ly-44 antibody; MGC3969 antibody; Ms4a1 antibody; MS4A1 antibody; MS4A2 antibody; B1 antibody; S7 antibody; Bp35 antibody; CD20 antibody; CVID5 antibody; MS4A2 antibody; LEU-16 antibody; Cd20 antibody; Ly-44 antibody; Ms4a2 antibody; AA960661 antibody

Rabbit IgG

This antibody was obtained from a rabbit immunized with purified, Human CD20 Transfected CHO Cells and conjugated with PE under optimum conditions, the unreacted PE was removed.

Monoclonal

Aqueous solution containing 0.5% BSA and 0.09% sodium azide

This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

FCM

CD20 (membrane-spanning 4-domains, subfamily A, member 1), also known as MS4A1, is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells, but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.

• Tedder TF, et al. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci. 85(1): 208-12.
• Cragg MS, et al. (2005) The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 8: 140-74..
• Polyak MJ, et al. (2003) A cholesterol-dependent CD20 epitope detected by the FMC7 antibody. Leukemia. 17(7): 1384-9.